Affiliation of authors: Division of Nutritional Epidemiology, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Correspondence to: Susanna C. Larsson, LicMSc, Division of Nutritional Epidemiology, The National Institute of Environmental Medicine, Karolinska Institutet, P.O. Box 210, SE-171 77 Stockholm, Sweden (e-mail: susanna.larsson{at}ki.se).
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Although epidemiologic studies of the relationship of diabetes with the risk of colorectal cancer are not entirely consistent, most studies are compatible with a positive association. In some studies, the association appeared to be stronger for colon cancer than for rectal cancer (912), or the association was observed only in women (10,13,14). The interpretation of these findings, however, has been hampered by the low frequency at which both diseases occur in the same individual, which results in the lack of statistical power to adequately analyze this association.
To provide a quantitative assessment of the association between diabetes and risk of colorectal cancer, we conducted a meta-analysis of casecontrol and cohort studies. We also evaluated whether the association varied by sex and by cancer subsite (colon versus rectum and proximal colon versus distal colon).
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We identified studies by a literature search of the Medline database (from January 1, 1966, through July 31, 2005) with the following medical subject heading terms and/or text words: "diabetes mellitus," "diabetes," "colorectal cancer," "colorectal neoplasm," "colon cancer," "colon neoplasm," "rectal cancer," and "rectal neoplasm." We also reviewed reference lists of the identified publications for additional pertinent studies. No language restrictions were imposed.
Inclusion and Exclusion Criteria
The 25 studies considered for inclusion in this meta-analysis were casecontrol and cohort studies on the association between diabetes and the incidence of or mortality from colon, rectal, or colorectal cancer (933). Studies were excluded if they provided only an estimate of effect with no means to calculate a confidence interval or if the estimates were not adjusted by age. When there were multiple publications from the same population or cohort, only data from the most recent report were included. We excluded three candidate studies (1517) because of overlapping publications and one study (18) that reported only crude data that were not adjusted by age.
Data Extraction
The data that we extracted included publication data (the first author's last name, year of publication, and country of population studied), study design, number of exposed and unexposed subjects, control source (in casecontrol studies), follow-up period (for cohort studies), type of diabetes (type 1 or 2), risk estimates with their corresponding confidence intervals, and variables controlled for by matching or in the multivariable model. From each study, we extracted the risk estimates that reflected the greatest degree of control for potential confounders.
Statistical Analysis
We divided epidemiologic studies of the relationship between diabetes and colorectal cancer risk into three general types according to measure of relative risk (RR): casecontrol studies (odds ratio), cohort studies (incidence and/or mortality rate ratio), and cohort studies with an external comparison group (standardized incidence and/or mortality ratio). We conducted separate meta-analyses of colorectal cancer incidence and mortality. The measure of effect of interest is the relative risk. Because colorectal cancer is rare, the odds ratio in casecontrol studies and rate ratios in cohort studies yield similar estimates of relative risk (34). Cohort studies that reported standardized incidence/mortality ratio were analyzed separately.
Summary relative risk estimates with their corresponding 95% confidence intervals (CIs) were derived with the method of DerSimonian and Laird (35) by use of the assumptions of a random effects model, which incorporates between-study variability. We calculated a pooled relative risk and its corresponding 95% confidence interval for studies that reported only sex- and/or subsite-specific relative risks. Statistical heterogeneity between studies was evaluated with Cochran's Q test and the I2 statistic (36). Publication bias was assessed by constructing a funnel plot (37), by Begg's adjusted rank correlation test, and by Egger's regression asymmetry test (38).
For casecontrol studies and cohort studies that reported incidence rate ratios, we conducted subgroup meta-analyses to examine potential sources of heterogeneity, including study design, type of control subjects in casecontrol studies, sex, cancer subsite, and duration of follow-up for cohort studies. Statistical analyses were carried out with Stata, version 8.0 (Stata Corp, College Station, TX). P values that were less than .05 were considered statistically significant. All statistical tests were two-sided.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Twenty-one independent studies met the predefined inclusion criteria. Of these 21 studies, six were casecontrol studies (10,13,19,26,27,33) (Table 1), 11 were cohort studies that used incidence and/or mortality rate ratios as the measure of relative risk (9,11,14,20,2224,28,3032) (Table 2), and four were cohort studies that used standardized incidence and/or mortality ratio as the measure of relative risk (12,21,25,29) (Table 3). Eleven studies were conducted in the United States, eight in Europe, one in Australia, and one in Korea. Of the 15 cohort studies, incident colorectal cancer was the outcome in seven, mortality from colon, rectal, or colorectal cancer was the outcome in three, and colorectal cancer incidence and mortality were reported in five. In the primary meta-analysis of diabetes and colorectal cancer incidence, we included all six casecontrol studies (10,13,19,26,27,33) and the nine cohort studies that reported incidence rate ratios (9,11,14,20,22,24,28,30,31). These 15 studies included a total of 2 593 935 participants. The three cohort studies (12,21,25) that reported standardized incidence ratio were analyzed separately. For the meta-analysis of diabetes and colorectal cancer mortality, we included the six cohort studies that reported mortality rate ratio (11,20,23,28,30,32). These six studies enrolled a total of 2 523 580 participants.
|
|
|
Individual study results and the overall summary results for the six casecontrol and nine cohort studies of diabetes and colorectal cancer incidence are shown in Fig. 1. Eight of these 15 studies found a statistically significant positive association between diabetes and colorectal cancer incidence (range of individual RRs = 1.02 to 2.78; summary RR for all 15 studies = 1.30, 95% CI = 1.20 to 1.40). No heterogeneity among studies was found (Q = 17.9; Pheterogeneity = .21; I2 = 21.8%). In a sensitivity analysis in which one study at a time was excluded and the rest were analyzed, we detected a statistically significant positive association between diabetes and colorectal cancer incidence (range of summary RRs = 1.25 to 1.36; the lower limit of the 95% CI never crossed 1.0).
|
|
A positive association was observed between diabetes and colorectal cancer incidence in the three cohort studies that reported standardized incidence ratios (summary RR = 1.22, 95% CI = 1.07 to 1.40) (Table 3). The test for heterogeneity among these three studies was not statistically significant (Q = 4.52; Pheterogeneity = .10; I2 = 55.8%).
Colorectal Cancer Mortality
Of six cohort studies of diabetes and mortality from colon (23) or colorectal (11,20,28,30,32) cancer, three (11,30,32) reported a statistically significant positive association, and one (28) observed a nonstatistically significant 3.6-fold (RR = 3.60, 95% CI = 0.81 to 15.89) increase in colorectal cancer risk associated with diabetes (Table 2). When all six studies were analyzed, a positive association between diabetes and mortality from colorectal cancer was found (summary RR = 1.26, 95% CI = 1.05 to 1.50). However, there was statistically significant heterogeneity among studies (Q = 11.59; Pheterogeneity = .04; I 2 = 56.8%). A sensitivity analysis identified the study by Hu et al. (11) as contributing most to the heterogeneity. In an analysis excluding this study, the association between diabetes and mortality from colorectal cancer was weaker (summary RR = 1.19, 95% CI = 1.10 to 1.28), and the test for heterogeneity was not statistically significant (Q = 4.03; Pheterogeneity = .40; I 2 = 0.6%). The association between diabetes and colorectal cancer mortality did not differ statistically significantly by sex (Q = 0.10; Pheterogeneity = .75).
Of two cohort studies that reported standardized mortality ratios (21,29) (Table 3), one (21) reported a statistically significant approximately 1.5-fold increased risk of death from colorectal cancer among diabetic patients. The other study found no statistically significant association between diabetes and rectal cancer mortality (29).
Publication Bias
There was no funnel plot asymmetry for the association between diabetes and colorectal cancer risk (data not shown). P values for Begg's adjusted rank correlation test and Egger's regression asymmetry test were .79 and .28, respectively, indicating a low probability of publication bias.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Our analysis must be interpreted in the context of the limitations of the available data. Most of the studies did not distinguish between type 1 and type 2 diabetes. Because type 1 diabetes [which accounts for 5% to 10% of all diagnosed cases of diabetes (1)] may not be related to colorectal cancer (12,39), the magnitude of the association between diabetes and colorectal cancer risk may have been slightly underestimated. In addition, because diabetes is an underdiagnosed disease, some degree of misclassification of exposure to diabetes is likely to have occurred. Such nondifferential misclassification would also tend to attenuate the true relationship between diabetes and colorectal cancer. As in any meta-analysis, the possibility of publication bias is of concern. However, the results obtained from funnel plot analysis and formal statistical tests did not provide evidence for such bias.
Type 2 diabetes and colorectal cancer share similar risk factors, including physical inactivity and obesity (8). Thus, the observed increased risk of colorectal cancer associated with a history of diabetes may reflect confounding by these risk factors. However, a positive association between diabetes and colorectal cancer risk remained when we limited the meta-analysis to studies that controlled for physical activity and body mass index (summary RR = 1.34, 95% CI = 1.20 to 1.49).
Discrepancies among studies investigating the relationship of diabetes with colorectal cancer risk according to sex and cancer subsite may be attributable to small sample sizes that resulted in insufficient statistical power to detect some relationships in the individual studies. Because this meta-analysis included a large number of studies, we could assess the association according to sex and cancer subsite with high precision.
A relationship between diabetes and risk of colorectal cancer is biologically plausible. Type 2 diabetes is characterized by increased insulin concentrations during the early stage of the disease. Hyperinsulinemia (8) or factors related to insulin resistance, such as hyperglycemia or hypertriglyceridemia (40), have been associated with colorectal carcinogenesis. Insulin can stimulate cell proliferation through a minor pathway that involves the direct activation of the insulin receptor or insulin-like growth factor (IGF)-I receptor and a major pathway that acts through the inhibition of IGF binding proteins (in particular, IGFBP-1 and IGFBP-2), which may result in increased free and bioavailable IGF-I (41). An important role of insulin and IGF-I in colorectal carcinogenesis is supported by in vitro studies, animal models, and epidemiologic studies (4144). Epidemiologic studies of circulating concentrations of insulin, C-peptide (a marker of insulin secretion), or IGF-I have shown two- to threefold increased risks of colorectal cancer for individuals in the highest exposure categories, compared with those in the lowest exposure categories (24,4548). Furthermore, a recent study reported that chronic insulin therapy was associated with a statistically significant increase in colorectal cancer risk among patients with type 2 diabetes (49). Other mechanisms through which diabetes may be linked with the risk of colorectal cancer include slower bowel transit times in patients with diabetes, which could contribute to the increased exposure of colonic mucosa to potential carcinogens, and elevated concentrations of fecal bile acids associated with increased blood glucose and triglyceride concentrations (20,5052). Fecal bile acids have been shown to promote colorectal cancer in animal models (53).
Our results have important clinical and public health implications. In the United States, about 8% of adults have diabetes (54), and it has been predicted that the number of Americans with diagnosed diabetes will increase 165%, from 11 million in 2000 (prevalence of 4.0%) to 29 million in 2050 (prevalence of 7.2%) (55). Colorectal cancer is the second leading cause of cancer death in the United States and other Western countries (2,3). The prevalence of diabetes will probably increase as a result of the growing obesity epidemic, and thus this disease may contribute to the development of additional cases of colorectal cancers.
In summary, the results from this meta-analysis strongly support an association between diabetes and increased risk of colon and rectal cancer in both women and men. These findings provide evidence for a role of hyperinsulinemia or factors related to insulin resistance in colorectal carcinogenesis.
![]() |
NOTES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
(1) Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004;140:94550.
(2) Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:1030.
(3) Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74108.
(4) Schulze MB, Hu FB. Primary prevention of diabetes: what can be done and how much can be prevented? Annu Rev Public Health 2005;26:44567.[CrossRef][ISI][Medline]
(5) Fung TT, Schulze M, Manson JE, Willett WC, Hu FB. Dietary patterns, meat intake, and the risk of type 2 diabetes in women. Arch Intern Med 2004;164:223540.
(6) World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR). Food, nutrition and the prevention of cancer: a global perspective. Washington (DC): WCRF/AICR; 1997.
(7) Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002;31:92543.[Medline]
(8) Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995;6:16479.[CrossRef][ISI][Medline]
(9) Limburg PJ, Anderson KE, Johnson TW, Jacobs DR, Jr., Lazovich D, Hong CP, et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2005;14:1337.
(10) Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res 1997;57:478794.[Abstract]
(11) Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91:5427.
(12) Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:13605.
(13) Levi F, Pasche C, Lucchini F, La Vecchia C. Diabetes mellitus, family history, and colorectal cancer. J Epidemiol Community Health 2002;56:47980; author reply 480.
(14) Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001;84:41722.[CrossRef][ISI][Medline]
(15) Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:30714.[CrossRef][ISI][Medline]
(16) La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994;70:9503.[ISI][Medline]
(17) La Vecchia C, D'Avanzo B, Negri E, Franceschi S. History of selected diseases and the risk of colorectal cancer. Eur J Cancer 1991;27:5826.[ISI][Medline]
(18) Williams JC, Walsh DA, Jackson JF. Colon carcinoma and diabetes mellitus. Cancer 1984;54:30701.[ISI][Medline]
(19) Yang YX, Hennessy S, Lewis JD. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 2005;3:58794.[CrossRef][Medline]
(20) Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 1998;147:81625.[Abstract]
(21) Weiderpass E, Gridley G, Nyren O, Ekbom A, Persson I, Adami HO. Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst 1997;89:6601.
(22) Steenland K, Nowlin S, Palu S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev 1995;4:80711.
(23) Smith GD, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 1992;136:11104.[Abstract]
(24) Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:114754.
(25) Ragozzino M, Melton LJ, 3rd, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982;35:139.[CrossRef][ISI][Medline]
(26) O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985;38:43541.[CrossRef][ISI][Medline]
(27) Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399404.[Abstract]
(28) Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 2004;13:9159.
(29) Kessler II. Cancer mortality among diabetics. J Natl Cancer Inst 1970;44:67386.[ISI][Medline]
(30) Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194202.
(31) Larsson SC, Giovannucci E, Wolk A. Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care 2005;28:18057.
(32) Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:11607.
(33) La Vecchia C, Negri E, Decarli A, Franceschi S. Diabetes mellitus and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1997;6:100710.
(34) Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:130.[ISI][Medline]
(35) DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:17788.[CrossRef][ISI][Medline]
(36) Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:153958.[CrossRef][ISI][Medline]
(37) Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:62934.
(38) Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care: Meta-Analysis in Context. London (UK): BMJ Publishing Group; 2001.
(39) Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003;95:1797800.
(40) McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994;3:68795.
(41) Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131(11 Suppl):3109S20S.
(42) Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002;94:97280.
(43) Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002;62:10305.
(44) Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:134653.[CrossRef][ISI][Medline]
(45) Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:6205.
(46) Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592600.
(47) Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:54653.
(48) Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000;9:3459.
(49) Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004;127:104450.[CrossRef][ISI][Medline]
(50) Rafter JJ, Eng VW, Furrer R, Medline A, Bruce WR. Effects of calcium and pH on the mucosal damage produced by deoxycholic acid in the rat colon. Gut 1986;27:13209.[Abstract]
(51) Yang R, Arem R, Chan L. Gastrointestinal tract complications of diabetes mellitus. Pathophysiology and management. Arch Intern Med 1984;144:12516.[Abstract]
(52) Stadler J, Yeung KS, Furrer R, Marcon N, Himal HS, Bruce WR. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. Cancer Lett 1988;38:31520.[CrossRef][ISI][Medline]
(53) Debruyne PR, Bruyneel EA, Li X, Zimber A, Gespach C, Mareel MM. The role of bile acids in carcinogenesis. Mutat Res 2001;480481:35969.
(54) Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:769.
(55) Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:193640.
Manuscript received May 4, 2005; revised September 12, 2005; accepted September 30, 2005.
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |